

- High-density lipoprotein (HDL)
atherosclerosis and, 291e-2, 291e-6
composition of, 2436-2437, 2436f, 2436t
low levels of, 291e-6, 2445-2446, 2451. *See also* Lipoprotein disorders
in metabolic syndrome, 2454
metabolism of, 2437-2438, 2438f
very high levels of, 2446
- High endothelial venules (HEVs), 372e-26
- High-frequency ventilation, 1738, 1739t, 1742.
See also Mechanical ventilation
- Highly active antiretroviral therapy (HAART).
See Combination antiretroviral therapy (cART)
- High-molecular-weight kininogen deficiency, 733t
- High-sensitivity C-reactive protein (hs-CRP), in HIV infection, 1249t
- Hinchey classification, of diverticulitis, 1972, 1972f
- Hip(s)
bursitis of, 2222, 2222f, 2247
fracture of
 bisphosphonates for prevention of, 2499-2500, 2500f
 denosumab for prevention of, 2501, 2502f
 in elderly women, 6e-4
 epidemiology of, 2488-2489, 2489f
 lifetime cumulative risk of, 27t
 management of, 2495
 PPIs and, 1921
 risk screening for, 28
 osteoarthritis of, 2228, 2230
 pain in, 112, 2222, 2222f, 2230
- Hip replacement, 2233
- Hirata's syndrome (insulin autoimmune syndrome), 2348
- Hirsutism, **331**
after menopause, 332
approach to the patient, 332, 334f
drug-induced, 331t, 332, 380
etiology of, 331, 331t
hormonal evaluation in, 332-333
in 21-hydroxylase deficiency, 2355
prevalence of, 2254t
scoring scale for, 332, 333f
screening/testing for, 2254t
treatment of, 334-335
- Hirudin, 2747
- His bundle, 273e-1, 1471
- His bundle electrogram, 1472f, 1474
- Histamine, 88f, 372e-15t
- Histamine H₁ receptor antagonists. *See* Antihistamines
- Histamine H₂ receptor antagonists
adverse effects of, 1920
for angioedema, 2119
drug interactions of, 42t, 246e-3t
for gastritis, 277
for GERD, 263, 1908
for peptic ulcer disease, 1920, 1920t
for premedication in chemotherapy, 1798
for systemic mastocytosis, 2121
for urticaria, 2119
for ZES, 568
- Histidine metabolism disorders, 434e-2t
- Histidinemia, 434e-2t
- Histidinuria, 435e-1t
- Histiocytosis, 135e-9, 441e-16f
- Histiocytosis X (Langerhans cell histiocytosis), 135e-9, 1713, 2257, 2264
- Histone(s), 102e-7, 430, 431f
- Histone acetylase, 102e-7
- Histone deacetylase (HDAC), 102e-7, 102e-8f
- Histone deacetylase-2, 1677, 1701
- Histone deacetylase (HDAC) inhibitors, 102e-7-8, 102e-8f, 103e-18t, 103e-19-20
- Histone H2A-H2B-DNA, 372e-24t
- Histoplasma capsulatum*, 145e-3, 1330, 1332, 1332f, 1333f
- Histoplasma* spp. infections, **1332**
clinical features of, 1333
 arthritis, 836, 837f
 cavitary, 1333
 chronic meningitis, 908t
 cutaneous, 366
 laryngitis, 234
 lymphadenopathy, 408, 1333
 mediastinitis, 1333
 oral, 239t
 subacute meningitis, 898-899
complications of, 1333
diagnosis of, 152e-4t, 1332f, 1333, 1333f
disseminated
 clinical course of, 1333
 in HIV infection, 1252t, 1255, 1268
 treatment of, 1334, 1334t
epidemiology of, 1332
incubation period for, 152e-4t
pathogenesis of, 1332
of pons, 441e-6f
prevention of, 152e-4t
in returning war veterans, 152e-4t
in transplant recipient, 925t
treatment of, 152e-4t, 899, 1333-1334, 1334t
- Histotoxic hypoxia, 248
- HIV
adherence of, 145e-1, 145e-2t
antibodies to, 1243-1244, 1243f
binding and fusion with target cell, 1216-1217, 1218f
cell membrane interactions of, 214e-1, 214e-3
cellular targets of, 1236
gene expression and replication in, 214e-4
genome of, 1218-1219, 1219f
genotypes of, 773, 774
geographic distribution of, 1220f
molecular heterogeneity of, 1219-1220
mutations in, 214e-5
persistent infections, mechanism of, 214e-7
phylogeny of, 1216, 1216f
receptors and co-receptors of, 1234-1235, 1236f
replication cycle of, 1216-1218, 1218f
resistance to, 145e-4
structure of, 225e-1-2, 225e-2f, 1216, 1217f
subtypes of, 1216, 1216f
viral release of, 145e-9
- HIV-1, 1216, 1216f, 1219-1220, 1219f, 1220f. *See also* HIV; HIV infection
- HIV-2, 1216, 1216f
- HIV-associated dementia (HAD), 1263, 1264t, 1265f
- HIV-associated neurocognitive disorders (HAND), 1241, 1263, 1264t, 1265f
- HIV infection
acute syndrome, 1228, 1249, 1249f
arthritis syndromes in, 837
asymptomatic stage (clinical latency), 1231, 1249-1250
cardiovascular disease in, 290e-1t, 1255, 1560, 1574
as chronic disease, 13-14
cobalamin deficiency in, 645-646
depression in, 2714
diagnosis of, 150e-7-8, **1245**
 algorithm for, 1245-1246, 1246f
 bDNA assay, 1247, 1247t
 enzyme immunoassay, 1245
 NABSA, 1247, 1247t
 p24 antigen capture assay, 770, 1243f, 1246-1247, 1247t
 point-of-care tests, 1246
 RT-PCR, 1247, 1247t
 Western blot, 1245, 1246f
drug allergies in, 384, 1260
drug interactions in, 798
drug resistance in, 773
drug toxicity in, 2030
elite nonprogressor, 1250
endocrine and metabolic disorders in
 adrenal insufficiency, 310
 hypogonadism, 1260, 2364
 lipodystrophy, 2450
 metabolic syndrome, 1259
 osteonecrosis, 1261
 osteoporosis, 1261
- SIADH, 1259
thyroid disorders, 1259-1260
- epidemiology of
 global, 8, 12, 869, 1219-1220, 1220f, 1223-1225, 1224f
 in infants and children, 1226, 1226f, 1227f
 racial/ethnic disparities in, 1225-1226, 1226f, 1227f
 in U.S., 12, 1225-1227, 1225f, 1226f, 1227f
gastrointestinal disease in, **1256**
 diarrhea, 266, 1257, 1257f
 esophagitis, 1256, 1256f, 1909-1910, 1910f
 HIV enteropathy, 1257
 infections, 1256-1257
 proctocolitis, 266
generalized wasting in, 1268
genetic considerations in
 abacavir-associated hypersensitivity, 1241
 chemokine receptors, 1239, 1240t
 chemokines, 1240t
 cytokines, 1240t
 gene-gene interactions, 1241t
 MHC locus genes, 1239
 phenotypes of susceptibility and response, 1238-1239
 specific conditions and, 1241, 1241t
genitourinary tract infections in, 1258-1259
 chancroid, 1012
 gonococcal, 1006-1007
 syphilis, 1138, 1138t
 warts, 1198
- health care workers and, 918, 1222-1223, 1283-1284
- hearing loss in, 219
- hematopoietic system disease in
 anemia, 1262
 bone marrow suppression, 1261-1262, 1261t
 lymphadenopathy, 408, 1232, 1270
 monoclonal gammopathy of undetermined significance, 1262
 monocyte dysfunction, 422
 neutropenia, 1262
 thrombocytopenia, 727, 728, 1262
 VTE, 1262
- in hemophiliacs, 734, 735
- hepatobiliary disease in, 1258
 cholangiopathy, 285, 2086
 drug-induced, 2030
 hepatitis, 1258, 1273, 2039, 2048-2049
 liver transplantation for, 2069
 pancreatitis, 1258, 2097-2098
- hyperkalemia in, 64e-2, 310
- idiopathic CD4+ T lymphocytopenia in, 1272
- immune reconstitution inflammatory syndrome in, 205e-1, 1112-1113, 1254, 1261, 1261t
- immune response to, **1242**, 1243f
 cell-mediated, 1243t, 1244-1245
 humoral, 1243-1244, 1243f, 1243t, 1244f
- immunizations in, 788f, 798, 1252-1253t
- immunologic and rheumatologic disease in, 1260-1261
- in infants and children, 1226, 1226f
- KIRs with, 372e-15t
- laboratory monitoring of
 CD4+ T cell counts, 1247-1248, 1248f
 co-receptor tropism assays, 1248-1249
 D-dimer, 1249t
 HIV resistance testing, 1248
 HIV RNA determinations, 1248
 hs-CRP, 1249t
 IL-6, 1249t
- long-term nonprogressor, 1250
- long-term survivor, 1231
- natural history of, 771f
- neoplastic disease in
 anal cancer, 544, 1198, 1271-1272
 cervical cancer, 1198
 HPV-related, 1198
 invasive cervical cancer, 1271-1272
 Kaposi's sarcoma. *See* Kaposi's sarcoma
 lymphomas, 1270-1271, 1271f
 multicentric Castleman's disease, 1271